Update on the management of vasoproliferative tumour

Arch Soc Esp Oftalmol (Engl Ed). 2018 Jul;93(7):350-353. doi: 10.1016/j.oftal.2018.01.005. Epub 2018 Feb 16.
[Article in English, Spanish]

Abstract

Case report: Here we report a 19-year-old female patient who presented a vasoproliferative tumour. It caused complications, such as epiretinal membrane, macular oedema, vitreous haemorrhage, and exudative retinal detachment. The patient was treated with 3 injections of intravitreal bevacizumab, an intravitreal dexamethasone implant, tocilizumab, and double freeze-thaw cryotherapy.

Discussion: Therapeutic options are: observation, if it is small, if it is a peripheral lesion, and if there seems to be no threat to vision. If it requires treatment, laser photocoagulation, intravitreal bevacizumab, trans-conjunctival cryotherapy, transpupillary thermotherapy, photodynamic therapy, brachytherapy plaques and surgery are the different options available. Recently, tocilizumab and intravitreal dexamethasone implants have been reported to be beneficial.

Keywords: Bevacizumab intravítreo; Crioterapia; Cryotherapy; Dexamethasone implant; Implante de dexametasona; Intravitreal bevacizumab; Tocilizumab; Tumor vasoproliferativo; Vasoproliferative tumour.

Publication types

  • Case Reports

MeSH terms

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antineoplastic Agents, Immunological / administration & dosage
  • Bevacizumab / administration & dosage
  • Combined Modality Therapy
  • Cryotherapy
  • Dexamethasone / administration & dosage
  • Female
  • Glucocorticoids / administration & dosage
  • Humans
  • Intravitreal Injections
  • Retinal Neoplasms / therapy*
  • Young Adult

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • Glucocorticoids
  • Bevacizumab
  • Dexamethasone
  • tocilizumab